Prof. Fabrice Barlesi, MD, PhD [7505]


What is the importance of finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib? (French)

What is the importance of finding EGFR sensitizing mutations such as exon 19 or exon 21 in NSCLC? What is their relationship to sensitivity to TKIs, such as erlotinib, gefitinib, and afatinib? (French)

What specific, targeted drugs are aligned with EGFR mutations, and how do you select among them based on genomic alterations detected by NGS? And what is the significance of detecting ROS 1 rearrangements? (French)

What specific, targeted drugs are aligned with EGFR mutations, and how do you select among them based on genomic alterations detected by NGS? And what is the significance of detecting ROS 1 rearrangements? (French)

How do you recommend navigating through the common scenario in which there are co-existing actionable mutations or molecular rearrangements in NSCLC? (French)

How do you recommend navigating through the common scenario in which there are co-existing actionable mutations or molecular rearrangements in NSCLC? (French)

How should medical oncologists deploy NGS-based, hybrid capture technology to optimize treatment outcomes and make more precise molecular target-therapeutic alignments in the setting of NSLC? (French)

How should medical oncologists deploy NGS-based, hybrid capture technology to optimize treatment outcomes and make more precise molecular target-therapeutic alignments in the setting of NSLC? (French)